<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647933</url>
  </required_header>
  <id_info>
    <org_study_id>P07004</org_study_id>
    <secondary_id>38802</secondary_id>
    <nct_id>NCT00647933</nct_id>
  </id_info>
  <brief_title>An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)</brief_title>
  <official_title>An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 After a Single Subcutaneous Dose in Healthy Female Volunteers Whose Pituitary Function is Suppressed by Lyndiol®.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study were to study the pharmacokinetics, pharmacodynamics and safety
      of Org 36286 after a single subcutaneous administration in healthy females.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">December 2000</completion_date>
  <primary_completion_date type="Actual">December 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum number of follicles &gt;= 5 mm (nmax)</measure>
    <time_frame>Days 2 - 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean dose-normalized maximum plasma concentration (Cmax) post single dose Org 36286</measure>
    <time_frame>Days 1 - 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean dose-normalized area under the curve (AUC) post single dose Org 36286</measure>
    <time_frame>Days 1 - 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean total plasma clearance (CL) post single dose Org 36286</measure>
    <time_frame>Days 1 - 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an adverse event (AE)</measure>
    <time_frame>Start of treatment up to day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Day on which the number of follicles &gt;= 5 mm was equal to nmax for the first time (dmax)</measure>
    <time_frame>Days 2 - 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of follicles &gt;= 5 mm per day</measure>
    <time_frame>Days 2 - 35</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Org 36286 15 μg + Lyndiol®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 15 μg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Org 36286 30 μg + Lyndiol®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 30 μg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Org 36286 60 μg + Lyndiol®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 60 μg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Org 36286 120 μg + Lyndiol®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 120 μg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Org 36286</intervention_name>
    <description>Subcutaneous Org 36286</description>
    <arm_group_label>Org 36286 15 μg + Lyndiol®</arm_group_label>
    <arm_group_label>Org 36286 30 μg + Lyndiol®</arm_group_label>
    <arm_group_label>Org 36286 60 μg + Lyndiol®</arm_group_label>
    <arm_group_label>Org 36286 120 μg + Lyndiol®</arm_group_label>
    <other_name>Corifollitropin alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lyndiol®</intervention_name>
    <description>Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.</description>
    <arm_group_label>Org 36286 15 μg + Lyndiol®</arm_group_label>
    <arm_group_label>Org 36286 30 μg + Lyndiol®</arm_group_label>
    <arm_group_label>Org 36286 60 μg + Lyndiol®</arm_group_label>
    <arm_group_label>Org 36286 120 μg + Lyndiol®</arm_group_label>
    <other_name>50 μg ethinylestradiol + 2.5 mg lynestrenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good physical and mental health;

          -  Body Mass Index between 18 and 29 kg/m^2;

          -  Good venous accessibility;

        Exclusion Criteria:

          -  Clinically relevant abnormal blood chemistry, hematology and/or urinalysis at
             screening;

          -  Hypertension (sitting diastolic blood pressure &gt; 90 mmHg and/or systolic blood
             pressure &gt; 150 mmHg);

          -  Contraindications for the use of oral contraceptives or gonadotropins;

          -  PAP-smear (= III) according to the Papanicolaou classification;

          -  History of endocrine abnormalities such as hyperprolactinaemia, polycystic ovary
             syndrome or any evidence of ovarian dysfunction;

          -  Primary ovarian failure;

          -  Ovarian cysts or enlarged ovaries, not related to polycystic ovarian disease;

          -  Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound
             investigation;

          -  Ovarian surgery;

          -  Smoking more than 10 cigarettes or equivalents a day;

          -  History (within 12 months) of alcohol or drugs abuse;

          -  Blood donation (&gt; 200 ml) within 90 days prior to screening;

          -  Administration of investigational drugs within 90 days prior to start Org 36286.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>June 26, 2015</last_update_submitted>
  <last_update_submitted_qc>June 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Females</keyword>
  <keyword>Corifollitropin alfa</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Mestranol</mesh_term>
    <mesh_term>Noracycline</mesh_term>
    <mesh_term>Lynestrenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

